https://www.selleckchem.com/products/mycro-3.html
-3.4). In this IPDMA, we found no differences in composite outcome between nifedipine and atosiban in the treatment of threatened preterm birth. However, the non-significant higher mortality after administering nifedipine warrants further investigation of the use of nifedipine as a tocolytic drug. We conducted this study according to a prospectively prepared protocol, registered with PROSPERO (the International Prospective Register of Systematic Reviews) under CRD42016024244. We conducted this study according to a prospectively prepared
Beğen
Yorum Yap
Paylaş
